{"id":56901,"date":"2026-02-11T22:11:13","date_gmt":"2026-02-11T14:11:13","guid":{"rendered":"https:\/\/flcube.com\/?p=56901"},"modified":"2026-02-11T22:11:14","modified_gmt":"2026-02-11T14:11:14","slug":"gsks-rsv-vaccine-filing-accepted-by-nmpa-for-china-market-entry","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56901","title":{"rendered":"GSK\u2019s RSV Vaccine Filing Accepted by NMPA for China Market Entry"},"content":{"rendered":"\n

GlaxoSmithKline plc<\/strong> (GSK, NYSE:\u202fGSK<\/a><\/strong>) announced that the Center for Drug Evaluation (CDE)<\/strong> of China’s NMPA<\/strong> has accepted for review<\/strong> its marketing application for the recombinant respiratory syncytial virus (RSV) vaccine<\/strong> (CHO cell, AS01E adjuvant system). The prefusion F protein-based vaccine<\/strong>, already approved in 65+ countries for adults 60+<\/strong>, targets lower respiratory tract disease (LRTD) prevention<\/strong> in China’s rapidly aging population<\/strong>, with CDE decision anticipated in 2027<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>GlaxoSmithKline plc (NYSE:\u202fGSK)<\/td><\/tr>
Agency<\/strong><\/td>CDE\/NMPA (China)<\/td><\/tr>
Asset<\/strong><\/td>Recombinant RSV vaccine (CHO cell, AS01E adjuvant)<\/td><\/tr>
Filing Status<\/strong><\/td>Marketing application accepted for review<\/td><\/tr>
Target Population<\/strong><\/td>Adults aged 60 years and older (initial indication)<\/td><\/tr>
Anticipated Decision<\/strong><\/td>2027<\/td><\/tr>
Global Approvals<\/strong><\/td>65+ countries (60+ years); 60+ countries including US\/Japan (50-59 high-risk); EEA (18+ years)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Vaccine Technology & Clinical Profile<\/h2>\n\n\n\n
Component<\/th>Specification<\/th>Strategic Advantage<\/th><\/tr><\/thead>
Antigen<\/strong><\/td>RSVPreF3<\/strong> \u2013 Recombinant glycosylated RSV F protein in prefusion conformation<\/strong><\/td>Stabilized structure elicits superior neutralizing antibody response<\/strong> vs. post-fusion alternatives<\/td><\/tr>
Manufacturing<\/strong><\/td>CHO cell expression system<\/strong><\/td>Scalable, high-yield production; established GSK biologics platform<\/td><\/tr>
Adjuvant<\/strong><\/td>AS01E proprietary adjuvant system<\/strong><\/td>Enhanced immunogenicity in older adults; dose-sparing potential<\/td><\/tr>
Administration<\/strong><\/td>Reconstitution required prior to injection<\/td>Standard vaccine preparation; healthcare professional administration<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Competitive Positioning<\/h2>\n\n\n\n
Factor<\/th>Strategic Analysis<\/th><\/tr><\/thead>
China RSV Burden<\/strong><\/td>>200 million adults aged 60+<\/strong>; RSV LRTD causes significant hospitalization and mortality<\/strong> in elderly; no approved RSV vaccines currently available<\/strong> in China<\/td><\/tr>
First-Mover Advantage<\/strong><\/td>GSK Arexvy<\/strong> and Pfizer Abrysvo<\/strong> raced for global approval (2023); GSK CDE filing acceptance<\/strong> positions for potential first China RSV vaccine launch<\/strong><\/td><\/tr>
Aging Population Policy<\/strong><\/td>“Healthy China 2030” prioritizes elderly vaccination<\/strong>; RSV vaccine aligns with pneumonia prevention<\/strong> initiatives<\/td><\/tr>
Competitive Landscape<\/strong><\/td>Pfizer Abrysvo<\/strong> likely concurrent NMPA review; Moderna mRNA-1345<\/strong> in development; GSK’s AS01E adjuvant differentiation<\/strong> may drive efficacy preference<\/td><\/tr>
Expansion Potential<\/strong><\/td>50-59 high-risk indication<\/strong> (approved US\/Japan) and broader adult indication<\/strong> (EEA) provide label expansion runway<\/strong> post-initial approval<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Development & Commercial Outlook<\/h2>\n\n\n\n
Phase<\/th>Activity<\/th>Timeline<\/th><\/tr><\/thead>
Current<\/strong><\/td>CDE review ongoing; technical and clinical data assessment<\/td>2026-2027<\/td><\/tr>
Approval<\/strong><\/td>NMPA marketing authorization anticipated<\/td>2027<\/strong><\/td><\/tr>
Launch<\/strong><\/td>Elderly vaccination campaign; hospital and clinic distribution<\/td>2027-2028<\/td><\/tr>
Expansion<\/strong><\/td>50-59 high-risk and 18+ adult indications<\/td>Post-approval submissions<\/td><\/tr>
Manufacturing<\/strong><\/td>Local supply chain establishment or importation strategy<\/td>2026-2027<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding GSK RSV vaccine CDE review timelines, NMPA approval outcomes, and China market commercialization success. Actual results may differ due to regulatory review delays, competitive dynamics with Pfizer Abrysvo, and elderly vaccination adoption rates in China’s healthcare system.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

GlaxoSmithKline plc (GSK, NYSE:\u202fGSK) announced that the Center for Drug Evaluation (CDE) of China’s NMPA…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[278,184,38,914,12],"class_list":["post-56901","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-glaxosmithkline","tag-gsk","tag-market-approval-filings","tag-nyse-gsk","tag-vaccine"],"yoast_head":"\nGSK\u2019s RSV Vaccine Filing Accepted by NMPA for China Market Entry - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GlaxoSmithKline plc (GSK, NYSE:\u202fGSK) announced that the Center for Drug Evaluation (CDE) of China's NMPA has accepted for review its marketing application for the recombinant respiratory syncytial virus (RSV) vaccine (CHO cell, AS01E adjuvant system). The prefusion F protein-based vaccine, already approved in 65+ countries for adults 60+, targets lower respiratory tract disease (LRTD) prevention in China's rapidly aging population, with CDE decision anticipated in 2027.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56901\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK\u2019s RSV Vaccine Filing Accepted by NMPA for China Market Entry\" \/>\n<meta property=\"og:description\" content=\"GlaxoSmithKline plc (GSK, NYSE:\u202fGSK) announced that the Center for Drug Evaluation (CDE) of China's NMPA has accepted for review its marketing application for the recombinant respiratory syncytial virus (RSV) vaccine (CHO cell, AS01E adjuvant system). The prefusion F protein-based vaccine, already approved in 65+ countries for adults 60+, targets lower respiratory tract disease (LRTD) prevention in China's rapidly aging population, with CDE decision anticipated in 2027.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56901\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-11T14:11:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-11T14:11:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56901#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56901\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK\u2019s RSV Vaccine Filing Accepted by NMPA for China Market Entry\",\"datePublished\":\"2026-02-11T14:11:13+00:00\",\"dateModified\":\"2026-02-11T14:11:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56901\"},\"wordCount\":408,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"GlaxoSmithKline\",\"GSK\",\"Market approval filings\",\"NYSE: GSK\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56901#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56901\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56901\",\"name\":\"GSK\u2019s RSV Vaccine Filing Accepted by NMPA for China Market Entry - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-11T14:11:13+00:00\",\"dateModified\":\"2026-02-11T14:11:14+00:00\",\"description\":\"GlaxoSmithKline plc (GSK, NYSE:\u202fGSK) announced that the Center for Drug Evaluation (CDE) of China's NMPA has accepted for review its marketing application for the recombinant respiratory syncytial virus (RSV) vaccine (CHO cell, AS01E adjuvant system). The prefusion F protein-based vaccine, already approved in 65+ countries for adults 60+, targets lower respiratory tract disease (LRTD) prevention in China's rapidly aging population, with CDE decision anticipated in 2027.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56901#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56901\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56901#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK\u2019s RSV Vaccine Filing Accepted by NMPA for China Market Entry\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK\u2019s RSV Vaccine Filing Accepted by NMPA for China Market Entry - Insight, China's Pharmaceutical Industry","description":"GlaxoSmithKline plc (GSK, NYSE:\u202fGSK) announced that the Center for Drug Evaluation (CDE) of China's NMPA has accepted for review its marketing application for the recombinant respiratory syncytial virus (RSV) vaccine (CHO cell, AS01E adjuvant system). The prefusion F protein-based vaccine, already approved in 65+ countries for adults 60+, targets lower respiratory tract disease (LRTD) prevention in China's rapidly aging population, with CDE decision anticipated in 2027.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56901","og_locale":"en_US","og_type":"article","og_title":"GSK\u2019s RSV Vaccine Filing Accepted by NMPA for China Market Entry","og_description":"GlaxoSmithKline plc (GSK, NYSE:\u202fGSK) announced that the Center for Drug Evaluation (CDE) of China's NMPA has accepted for review its marketing application for the recombinant respiratory syncytial virus (RSV) vaccine (CHO cell, AS01E adjuvant system). The prefusion F protein-based vaccine, already approved in 65+ countries for adults 60+, targets lower respiratory tract disease (LRTD) prevention in China's rapidly aging population, with CDE decision anticipated in 2027.","og_url":"https:\/\/flcube.com\/?p=56901","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-11T14:11:13+00:00","article_modified_time":"2026-02-11T14:11:14+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56901#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56901"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK\u2019s RSV Vaccine Filing Accepted by NMPA for China Market Entry","datePublished":"2026-02-11T14:11:13+00:00","dateModified":"2026-02-11T14:11:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56901"},"wordCount":408,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["GlaxoSmithKline","GSK","Market approval filings","NYSE: GSK","Vaccine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56901#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56901","url":"https:\/\/flcube.com\/?p=56901","name":"GSK\u2019s RSV Vaccine Filing Accepted by NMPA for China Market Entry - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-11T14:11:13+00:00","dateModified":"2026-02-11T14:11:14+00:00","description":"GlaxoSmithKline plc (GSK, NYSE:\u202fGSK) announced that the Center for Drug Evaluation (CDE) of China's NMPA has accepted for review its marketing application for the recombinant respiratory syncytial virus (RSV) vaccine (CHO cell, AS01E adjuvant system). The prefusion F protein-based vaccine, already approved in 65+ countries for adults 60+, targets lower respiratory tract disease (LRTD) prevention in China's rapidly aging population, with CDE decision anticipated in 2027.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56901#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56901"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56901#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK\u2019s RSV Vaccine Filing Accepted by NMPA for China Market Entry"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56901","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56901"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56901\/revisions"}],"predecessor-version":[{"id":56902,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56901\/revisions\/56902"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56901"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56901"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56901"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}